Takahara, Naminatsu
Nakai, Yousuke
Isayama, Hiroyuki
Sasaki, Takashi
Morine, Yuji
Watanabe, Kazuo
Ueno, Makoto
Ioka, Tatsuya
Kanai, Masashi
Kondo, Shunsuke
Okano, Naohiro
Koike, Kazuhiko
Funding for this research was provided by:
Japan Agency for Medical Research and Development (16lk0201052h)
The Tokyo University Research Fund
Article History
Received: 17 September 2022
Accepted: 22 November 2022
First Online: 2 December 2022
Declarations
:
: The authors declare no competing interests.
: This study was approved by the University of Tokyo, Clinical Research Review Board and was carried out in accordance with the guidelines for Good Clinical Practice.
: Written informed consent was obtained from all participants.
: All authors approved for the publication.
: Yousuke Nakai receives research fund from Taiho Pharma. Hiroyuki Isayama receives research fund from Yakult Honsha Co., Ltd. MU receives lecture fees, honoraria, or other fees from Yakult Honsha Co., Ltd. and research fund from Yakult Honsha Co., Ltd. Tatsuya Ioka receives lecture fees, honoraria, or other fees from Taiho Pharma and Ono pharmaceutical Co., Ltd. Masashi Kanai receives profit from shares of Therabiopharma Inc. and lecture fees, honoraria, or other fees from Chugai Pharmaceutical Co., Ltd. and research fund from Molecular health.